ADMA Biologics, Inc. Updates Financial Guidance for the Years 2023, 2024 and 2025
November 08, 2023 at 04:05 pm
Share
ADMA Biologics, Inc. updated financial guidance for the years 2023, 2024 and 2025. The company now anticipates fiscal year 2023 total revenues to exceed $250 million, increased from $240 million previously. Further, the company anticipates continued growth in Net Income over the remainder of 2023.
The company increased its intermediate term financial guidance, and now anticipates fiscal year 2024 and 2025 total revenues to exceed $290 million and $335 million, respectively, raised from at least $275 million and $320 million, respectively, previously.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
ADMA BIOLOGICS, INC. 
